Merck (MRK) Debt to Equity (2009 - 2026)

Merck has disclosed Debt to Equity across 18 years of filings, most recently posting $1.07 for Q1 2026.

• In Q1 2026, Debt to Equity rose 48.71% year-over-year to $1.07; the TTM figure through Mar 2026 stood at $1.07 (up 48.71% YoY), while the FY2025 annual figure was $0.94, up 17.07% from the prior year.
• Debt to Equity improved to $1.07 in Q1 2026, from $0.94 in the prior quarter.
• Over the last five years, Debt to Equity for MRK reached as high as $1.07 in Q1 2026 and fell as low as $0.66 in Q1 2023.
• The 5-year median for Debt to Equity is $0.8 (2024), against an average of $0.82.
• Annual changes were most pronounced in 2022 — Debt to Equity slumped 32.83% — and 2026, when it soared 48.71%.
• A 5-year view of Debt to Equity shows it stood at $0.67 in 2022, then surged by 39.78% to $0.93 in 2023, then fell by 14.08% to $0.8 in 2024, then grew by 17.07% to $0.94 in 2025, then rose by 14.27% to $1.07 in 2026.
• According to Business Quant data, Debt to Equity over the past three periods registered $1.07, $0.94, and $0.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.